Systemic glucocorticoid use in Denmark: a population-based prevalence study by Laugesen, K et al.
 1Laugesen K, et al. BMJ Open 2017;7:e015237. doi:10.1136/bmjopen-2016-015237
Open Access 
Systemic glucocorticoid use in 
Denmark: a population-based 
prevalence study
Kristina Laugesen,1 Jens Otto Lunde Jørgensen,2 Henrik Toft Sørensen,1 
Irene Petersen1,3 
To cite: Laugesen K, 
Jørgensen JOL, Sørensen HT, 
et al. Systemic glucocorticoid 
use in Denmark: a 
population-based 
prevalence study. BMJ Open 
2017;7:e015237. doi:10.1136/
bmjopen-2016-015237
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files please visit the 
journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2016- 
015237).
Received 18 November 2016
Revised 15 March 2017
Accepted 17 March 2017
1Department of Clinical 
Epidemiology, Aarhus University 
Hospital, Aarhus, Denmark
2Department of Endocrinology 
and Internal Medicine, Aarhus 
University Hospital, Aarhus, 
Denmark
3Department of Primary Care 
and Population Health, University 
College London, London, UK
Correspondence to
Kristina Laugesen;  
 kristina. laugesen@ clin. au. dk
Research
AbstrAct
Objectives Glucocorticoid (GC) use is widespread and 
associated with many adverse effects. Thus, it is important 
to ascertain GC utilisation patterns. In this study, we 
examined the annual prevalence of prescription users and 
amount of use of systemic GCs.
Design Population-wide prevalence study.
Setting The primary healthcare and hospital sectors in 
Denmark from 1999 to 2015.
Results Approximately 3% of the Danish population 
redeemed at least one prescription for a systemic GC 
annually between 1999 and 2015, with annual prevalence 
remaining constant over the period. However, after 
adjusting for age and sex, we observed a decrease in 
annual prevalence from 1999 to 2015, with a prevalence 
ratio of 0.92 (95% CI 0.91 to 0.92). Annual prevalence was 
highest among the elderly (7.0%–8.2% among persons 
65–79 years of age and 8.4%–10% among persons 
80+ years of age). Prednisolone was the most frequently 
redeemed systemic GC, with annual prevalence increasing 
from 1.4% to 2.1% during the 1999–2015 period. The 
amount of systemic GCs provided to the hospital sector 
increased from 2.3 defined daily doses (DDD)/1000 
inhabitants/day in 1999 to 3.5 DDD/1000 inhabitants/
day in 2015, while the amount provided to the primary 
healthcare sector remained constant in the range of 10–11 
DDD/1000 inhabitants/day.
Conclusion We found a high prevalence of systemic GC 
use of 3% with a remarkably high prevalence in elderly of 
up to 10%, wherefore continued awareness of its effects 
is mandated.
Background
Glucocorticoids (GCs) are potent anti-inflam-
matory drugs used widely since the 1950s to 
treat common conditions such as asthma, 
chronic obstructive pulmonary disease, 
chronic inflammatory bowel diseases, rheu-
matic diseases and malignancies.1 Besides 
their beneficial effects in treating inflamma-
tory diseases, GCs are associated with increased 
risk of a number of adverse outcomes, 
including iatrogenic adrenocortical insuf-
ficiency,2 venous thromboembolism3 and 
cardiac disease.4–6 In addition, GCs can cause 
metabolic diseases such as hyperglycaemia, 
diabetes7 and dyslipidaemia.8 They also are 
associated with increased risk of osteoporosis9 
and neuropsychiatric disorders.10
Current knowledge of GC utilisation 
patterns is in need of updating and expan-
sion. Earlier studies estimated that the 
prevalence of oral GC use is approximately 
1% in the UK and the US adult popula-
tions.11–13 In the current population-based 
study, we examined the annual prevalence of 
systemic GC prescription users (one or more 
redeemed prescriptions in a year) in the 
primary healthcare sector and ascertained 
the amount of GC used within the primary 
healthcare and hospital sectors in Denmark 
during 1999–2015.
MeThods
setting
Our study population included the entire 
Danish population from 1 January 1999 to 31 
December 2015. Denmark provides its entire 
Strengths and limitations of this study
 ► Current knowledge of glucocorticoid (GC) utilisation 
patterns is in need of updating and expansion.
 ► A strength of our study is the population-based 
design that enables us to assess utilisation of 
systemic GCs in the entire Danish nation from 1999 
to 2015.
 ► An additional advantage was the ability to assess 
GC use in the hospital sector as well as the primary 
healthcare sector, which is normally not captured 
when using Danish prescription registries for 
research.
 ► The results of this study apply only to redeemed 
prescriptions and sales of systemic GCs and not 
necessarily to actual adherence and use.
 ► As we used aggregated data, we were not able to 
address number of prescriptions at an individual 
level, to separate oral and injectable formulations, 
to obtain incidence use and to assess use of 
comedication.
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population (5.6 million) with universal tax-supported 
healthcare, guaranteeing free and equal access to general 
practitioners and hospitals and partial reimbursement for 
prescribed medications, including GCs. A unique central 
personal registration number (civil registration number) 
is assigned to all Danish residents at birth or on immi-
gration, enabling accurate and unambiguous linkage of 
relevant registries at the individual level.14
utilisation of systemic glucocorticoids in denmark
In Denmark, all systemic GCs (ATC code H02AB) are 
available by prescription only. We used Medstat (http://
www. medstat. dk) to retrieve data on systemic GC amount 
and prevalence of prescription users in Denmark.15 The 
publicly available Medstat website hosted by the Danish 
Serum Institute provides aggregate statistics on the sale 
of pharmaceutical preparations in Denmark since 1995, 
based on data reported to the Register of Medicinal 
Product Statistics.16 Aggregated Medstat statistics are 
complete from 1999 onwards and allow for extraction 
of both amount (in primary healthcare and hospital 
sector) and number of users (in primary healthcare) 
each year.15 Amount is expressed in defined daily doses 
(DDD)/1000 inhabitants/24 hours and can be assessed 
in primary healthcare sector, hospital sector and in total. 
DDD is developed by WHO and defined as the assumed 
average maintenance dose per day for a drug used for 
its main indication in adults.17 However, it should be 
emphasised that the DDD is a unit of measurement and 
does not necessarily reflect the recommended prescribed 
dose. As an example, the DDD for prednisolone is 10 mg 
per day. Medicines to the hospital sector are distributed 
to departments, and the people who are treated with the 
medicines are not reported; hence, only amount and not 
prevalence of users can be assessed in this sector. Use 
in primary healthcare includes individual dispensing of 
medicines in pharmacies. As the civil registration number 
is registered at each prescription redemption at phar-
macies in Denmark, we were able to retrieve number of 
prescription users in primary care in addition to amount 
and stratify on age and sex.
statistical analysis
First, we focused on prescriptions for systemic GCs in 
the primary healthcare sector. The annual prevalence of 
systemic GC prescription users was defined as the number 
of people who redeemed at least one prescription for a 
systemic GC each year divided by the number of people in 
the population each year (as of 1 January). We calculated 
overall annual prevalence and then stratified by sex and 
age group (0–4 years, 5–9 years, 10–14 years, 15–19 years, 
20–39 years, 40–64 years, 65–79 years and ≥80 years). Age 
was defined as the age at which the first prescription was 
redeemed each year. We further stratified on generic type 
of systemic GC. In our computation of the annual preva-
lence of GC use, the entire Danish population served as 
the reference group. When we computed the prevalence 
in subgroups (age and sex), the subgroup of interest 
served as the reference population. To examine changes 
in prevalence, we used a Poisson regression model to 
estimate adjusted prevalence ratios according to age, 
sex and calendar year. When comparing age groups, we 
adjusted for sex and calendar year; when comparing sex, 
we adjusted for age group and calendar year and when 
comparing calendar years, we adjusted for sex and age 
group. Finally, we calculated the amount (DDD/1000 
inhabitants/24 hours) of systemic GC used in total and 
according to healthcare sector (primary healthcare sector 
and hospital sector). We conducted our statistical analyses 
using Stata 12 for Windows (Stata Corp, College Station, 
TX, USA).
resulTs
In any given year between 1999 and 2015, 3% (range: 
3.0%–3.4%) of the total Danish population redeemed at 
least one prescription for a systemic GC (table 1). Overall, 
prevalence of systemic GC prescription users during this 
period, adjusted for age and sex, was fairly stable with a 
slight decrease towards the end of the period (table 2).
The annual prevalence of systemic GC prescription 
users was higher among women than among men with a 
prevalence ratio of 1.11 (95% CI 1.11 to 1.11) (table 2) 
and prevalence ranging from 3.3% to 3.7% in women 
and 2.7% to 3.1% in men (table 1). The prevalence of 
prescription users increased substantially with age. Thus, 
persons aged 40–64 were more than 10 times as likely and 
persons aged 80+ were more than 25 times as likely to 
receive GC treatment than those aged below 19 (table 2). 
While prevalence was relatively constant between 1999 
and 2015, the prevalence fell from 8.2% to 7.0% among 
persons aged 65–79 years and increased from 8.4% to 
10% among those aged 80 or above (table 1).
The most frequently redeemed systemic GC was pred-
nisolone. Its annual prevalence of redemption in the 
Danish population increased from 1.4% to 2.1% during 
1999 and 2015. In 2015, prednisolone accounted for 50% 
of all GC prescriptions redeemed in the period (taking 
into account only the first prescription each year). There 
was a decrease in redemptions of prednisone and beta-
methasone, from 0.4% to 0.1% and from 1.0% to 0.4% 
of the Danish population, respectively, from 1999 to 2015 
(figure 1).
The amount of systemic GC used in the primary health-
care sector consistently remained at 10 DDD/1000 
inhabitants/24 hours (range: 10.0–10.8 DDD/1000 
inhabitants/24 hours) from 1999 to 2015. The amount 
of systemic GCs used in the hospital sector increased 
from 2.3 DDD/1000 inhabitants/24 hours in 1999 to 3.5 
DDD/1000 inhabitants/24 hours in 2015 (table 3).
discussion
This population-based nationwide study found a high 
prevalence (3%) of systemic GC users from 1999 to 
2015 in Denmark, especially among the elderly (10%). 
This underscores the importance of clinical awareness of 
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the adverse effects of GC treatment. Still, when changes 
in the age structure of the population were taken into 
consideration, a minor decrease in prevalence of GC 
prescriptions users was observed during the study period. 
When assessing amount of systemic GC use, we observed a 
slight increase from 1999 to 2015, mainly due to inclined 
use in the hospital sector.
Previous studies conducted in UK and USA reported a 
lower prevalence of approximately 1%.11–13 However, UK 
and USA estimates were limited to the use of oral GCs. 
Our inclusion of all systemic GCs—both oral and inject-
able formulations—might explain in part the higher 
estimates of prevalence of use in the Danish population. 
Also, the UK study covered only long-term (≥1 year) GC 
use,11 while our study included all use. Still, the results 
from our study most likely reflect a higher use of systemic 
GCs in Denmark compared with UK and USA.
The UK study reported an increase in prescriptions 
for long-term oral GCs of nearly 34% between 1989 and 
2008.11 Our study found that overall annual prevalence 
did not vary substantially between 1999 and 2015. Taking 
into account changes in age and sex distribution of the 
population, we found a decrease in the annual preva-
lence of systemic GC prescription users towards the end 
of our study period. Due to use of aggregated data, we 
were not able to investigate long-term use.
Our finding that prednisolone was the most frequent 
subtype of redeemed GC prescription (50%) is consistent 
with the UK and US studies, which reported that 92.3% 
and 76.6% of total GC prescriptions were for predniso-
lone.11 13
The UK study found the highest prevalence of use 
of oral GCs among women aged 80–90 years (3.05% 
(95% CI 3.01% to 3.09%)) and the lowest prevalence 
among men aged 18–29 years (0.08% (95% CI 0.07% to 
0.09%)).11 In the US population, the highest prevalence 
of use was found among men aged ≥80 years (3.5% (95% 
CI 2.3% to 4.7%)) and among women aged 70–79 years 
(2.7% (95% CI 1.7% to 3.7%)).13 The high prevalence of 
GC use observed among the elderly in our study is note-
worthy, as it is well established that persons in the highest 
age groups are particularly prone to adverse outcomes 
due to higher levels of comorbidity, senescent changes in 
the body composition and polypharmacy.18
When assessing amount of systemic GC use, we 
observed an increase of use in the hospital sector. A 
possible explanation for this can be a higher frequency 
of elderly admitted to the Danish hospitals from 1999 to 
2015.19 When patients are hospitalised, treatment with 
medicine is not registered at an individual level in our 
national registries; hence, we were not able to examine 
use according to age; neither could we include GC use in 
the hospital sector in our prevalence analyses.
The pattern of disease has changed from 1999 to 
201411 20–22 with increasing prevalence of many inflam-
matory diseases. Despite this, we have observed a minor 
Table 1 Annual prevalence of systemic glucocorticoid (GC) prescription users in Denmark, 1999–2015, overall and stratified 
by sex and age group
Prevalence of prescription users (% of the national population)
All Sex Age groups (years)
Women Men 0–4 5–9 10–14 15–19 20–39 40–64 65–79 80+
1999 3.2 3.4 2.9 0.06 0.1 0.2 0.9 2.2 3.8 8.1 8.4
2000 3.3 3.6 3.0 0.06 0.1 0.2 1.0 2.4 3.9 8.1 8.7
2001 3.3 3.6 3.0 0.09 0.1 0.2 1.0 2.4 3.9 8.2 8.8
2002 3.3 3.6 3.0 0.06 0.1 0.3 1.1 2.6 3.9 8.1 8.9
2003 3.2 3.5 2.9 0.07 0.1 0.2 1.0 2.3 3.8 8.0 8.9
2004 3.2 3.5 2.9 0.06 0.1 0.2 0.9 2.3 3.8 8.0 8.9
2005 3.3 3.6 3.0 0.06 0.1 0.2 1.0 2.5 3.8 8.0 9.2
2006 3.4 3.7 3.0 0.07 0.1 0.3 1.1 2.5 4.0 8.0 9.3
2007 3.4 3.7 3.1 0.07 0.1 0.3 1.2 2.6 4.0 8.0 9.4
2008 3.4 3.7 3.1 0.07 0.1 0.3 1.2 2.6 3.9 7.7 9.5
2009 3.3 3.6 3.0 0.08 0.1 0.3 1.1 2.4 3.9 7.7 9.5
2010 3.3 3.6 2.9 0.07 0.1 0.2 1.0 2.2 3.8 7.6 9.7
2011 3.2 3.5 2.9 0.08 0.1 0.2 1.0 2.1 3.7 7.4 9.7
2012 3.1 3.4 2.8 0.07 0.1 0.2 0.9 2.0 3.6 7.2 9.7
2013 3.1 3.4 2.8 0.08 0.1 0.2 0.8 1.9 3.5 7.1 10
2014 3.1 3.4 2.8 0.07 0.1 0.2 0.8 1.9 3.5 7.0 9.8
2015 3.0 3.3 2.7 0.07 0.1 0.2 0.7 1.7 3.3 7.0 9.9
Reference group for all systemic GCs is all members of the Danish population as of 1 January in the year of interest. Reference groups for the 
stratified results are all members in the subpopulation of interest as of 1 January of each year.
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decrease in prevalence of systemic GC users when taking 
changes in age structure into account. An explanation 
for this can be an increased clinical awareness of the 
adverse effects of GC treatment as well as increased use 
of alternative immunomodulatory treatments. The use 
of methotrexate, azathioprine and anti-tumour necrosis 
factor alpha therapy has increased and newer biological 
agents have been approved for treatment in Denmark 
during our study period.15
The strength of our study includes its large nationwide 
study population making use capable of assessing utili-
sation of GCs in the entire Danish nation. In addition, 
we had the ability to assess GC use in the hospital sector. 
Many drug utilisation studies do not have available infor-
mation on prescribing in the hospital section. Hence, our 
study helps to inform which proportion of prescribing 
may be missing from such studies. However, this study 
also has limitations. First, the results of this study apply 
only to redeemed prescriptions and sales of systemic GCs 
and not necessarily to actual use or dose, as we were not 
able to estimate adherence to the medication. Second, 
Table 2 Prevalence ratios of redemption of systemic 
glucocorticoid prescriptions according to sex, age and 
calendar year, modelled using a multivariable Poisson 
regression
Prevalence ratios (95% CI)
Sex*
  Men 1 (ref)
  Women 1.11 (1.11 to 1.11)
Age groups (years)†
  0–19 1 (ref)
  20–39 6.84 (6.79 to 6.89)
  40–64 10.7 (10.7 to 10.8)
  65–79 21.3 (21.1 to 21.4)
  80+ 25.3 (25.1 to 25.5)
Calendar year‡
  1999 1 (ref)
  2000 1.03 (1.03 to 1.04)
  2001 1.03 (1.03 to 1.04)
  2002 1.05 (1.05 to 1.06)
  2003 1.01 (1.00 to 1.02)
  2004 1.02 (1.01 to 1.03)
  2005 1.04 (1.03 to 1.04)
  2006 1.06 (1.05 to 1.07)
  2007 1.06 (1.06 to 1.07)
  2008 1.06 (1.05 to 1.07)
  2009 1.05 (1.04 to 1.06)
  2010 1.02 (1.01 to 1.03)
  2011 1.00 (1.00 to 1.01)
  2012 0.97 (0.96 to 0.98)
  2013 0.95 (0.94 to 0.96)
  2014 0.95 (0.94 to 0.96)
  2015 0.92 (0.91 to 0.92)
*Prevalence ratios adjusted for age group and calendar year.
†Prevalence ratios adjusted for sex and calendar year.‡Prevalence 
ratios adjusted for sex and age group.
Figure 1 Annual prevalence of systemic glucocorticoid 
(GC) prescription users in Denmark, 1999–2015, overall 
and stratified by generic type. All systemic GCs (red line), 
prednisolone (dark blue line), betamethasone (green line), 
prednisone (orange line), methylprednisolone (blue line), 
triamcinolone (dark green line), hydrocortisone (purple line), 
dexamethasone (light blue line).
Table 3 Amount of systemic glucocorticoids sold to the 
primary healthcare sector, hospital sector and in total, 
Denmark, 1999–2015
Defined daily dose/1000 inhabitants/24 hours
Primary sector healthcare 
sector
Hospital 
sector Total
1999 10.4 2.3 12.7
2000 10.5 2.3 12.8
2001 10.8 2.3 13.1
2002 11.0 2.6 13.5
2003 10.8 2.5 13.3
2004 10.8 2.4 13.2
2005 10.8 2.5 13.3
2006 10.8 2.6 13.4
2007 10.7 2.7 13.4
2008 10.7 2.7 13.4
2009 10.6 3.0 13.6
2010 10.5 3.1 13.6
2011 10.3 3.1 13.5
2012 10.2 3.3 13.5
2013 10.1 3.4 13.5
2014 10.1 3.6 13.7
2015 10.0 3.5 13.5
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as we used aggregated data, we were not able to address 
number of redeemed prescriptions at an individual level, 
to separate oral and injectable formulations, to obtain 
incidence use and to assess use of comedication, which 
is all relevant when describing utilisation patterns. Third, 
our study did not aim to describe utilisation of inhaled 
and topical GCs; however, these formulations should also 
be considered important when addressing adverse effects.
In conclusion, this population-based nationwide study 
found a high prevalence of systemic GC use of 3% with 
remarkably high prevalence in the elderly of up to 10%, 
wherefore continued awareness of its adverse effects is 
mandated.
Contributors KL, IP, JOLJ and HTS made primary contributions to the study 
conception and wrote the manuscript. KL extracted results from Medstat (http://
www. medstat. dk/ en) and performed statistical analyses. KL, IP, JOLJ and HTS 
contributed to the interpretation of results and revised the manuscript critically. All 
authors approved the final manuscript. KL is the guarantor for this study.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4.0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
references
 1. Rasmussen Å.  Pro. medicin. dk . Information on glucocorticoid 
package sizes and indications in Denmark [in Danish]. 2016;2015.
 2. Broersen LH, Pereira AM, Jørgensen JO, et al. Adrenal insufficiency 
in corticosteroids use: systematic review and meta-analysis. J Clin 
Endocrinol Metab 2015;100:2171–80.
 3. Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use 
of glucocorticoids and risk of venous thromboembolism: a 
nationwide population-based case-control study. JAMA Intern Med 
2013;173:743–52.
 4. Fardet L, Petersen I, Nazareth I. Risk of cardiovascular events 
in people prescribed glucocorticoids with iatrogenic Cushing's 
syndrome: cohort study. BMJ 2012;345:e4928.
 5. Davis JM, Maradit Kremers H, Crowson CS, et al. Glucocorticoids 
and cardiovascular events in rheumatoid arthritis: a population-
based cohort study. Arthritis Rheum 2007;56:820–30.
 6. Christiansen CF, Christensen S, Mehnert F, et al. Glucocorticoid use 
and risk of atrial fibrillation or flutter: a population-based, case-
control study. Arch Intern Med 2009;169:1677–83.
 7. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. 
Endocr Pract 2009;15:469–74.
 8. Zimmerman J, Fainaru M, Eisenberg S. The effects of prednisone 
therapy on plasma lipoproteins and apolipoproteins: a prospective 
study. Metabolism 1984;33:521–6.
 9. van Staa TP, Leufkens HG, Cooper C. The epidemiology of 
corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos 
Int 2002;13:777–87.
 10. Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe 
neuropsychiatric disorders following glucocorticoid therapy in 
primary care. Am J Psychiatry 2012;169:491–7.
 11. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral 
glucocorticoid prescriptions in the UK over the past 20 years. 
Rheumatology 2011;50:1982–90.
 12. van Staa TP, et al. Use of oral corticosteroids in the United Kingdom. 
QJM 2000;93:105–11.
 13. Overman RA, Yeh J-Y, Deal CL. Prevalence of oral glucocorticoid 
usage in the United States: a general population perspective. 
Arthritis Care Res 2013;65:294–8.
 14. Pedersen CB. The Danish Civil Registration System. Scand J Public 
Health 2011;39:22–5.
 15. Anonymous, Danish Serum Institute. Statistics on the annual sale 
of medicines in Denmark based on the data from the Register of 
Medicinal Product Statistics. 2016;2016.
 16. Kildemoes HW, Sørensen HT, Hallas J. The Danish National 
prescription registry. Scand J Public Health 2011;39:38–41.
 17. WHO collaborating Centre for Drug Statistics Methodology. Definition 
and general considerations. 2016;2017.
 18. Bressler R, Bahl JJ. Principles of drug therapy for the elderly patient. 
Mayo Clin Proc 2003;78:1564–77.
 19. Sundheds- og ældreministeriet. Healthcare in Denmark- an overview. 
2016;2016.
 20. Hammer T, Nielsen KR, Munkholm P, et al. The Faroese IBD 
study: incidence of inflammatory bowel diseases across 54 
years of population-based data. Journal of Crohn's and Colitis 
2016:10:934–42.
 21. Minichiello E, Semerano L, Boissier M-C. Time trends in the 
incidence, prevalence, and severity of rheumatoid arthritis: a 
systematic literature review. Joint Bone Spine 2016;83:625–30.
 22. Simpson CR, Hippisley-Cox J, Sheikh A. Trends in the epidemiology 
of chronic obstructive pulmonary disease in England: a national 
study of 51 804 patients. Br J Gen Pract 2010;60:277–84.
group.bmj.com on July 17, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
population-based prevalence study
Systemic glucocorticoid use in Denmark: a
and Irene Petersen
Kristina Laugesen, Jens Otto Lunde Jørgensen, Henrik Toft Sørensen
doi: 10.1136/bmjopen-2016-015237
2017 7: BMJ Open 
 http://bmjopen.bmj.com/content/7/5/e015237
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/7/5/e015237
This article cites 18 articles, 3 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (2067)Epidemiology
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on July 17, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
